Literature DB >> 24106173

Distinct trajectories of disease activity over the first year in early rheumatoid arthritis patients following a treat-to-target strategy.

Liseth Siemons1, Peter M Ten Klooster, Harald E Vonkeman, Cees A W Glas, Mart a F J Van de Laar.   

Abstract

Objective: Although treat-to-target (T2T) strategies are effective in early RA patients, important individual variations exist in the course towards remission. Growth mixture modeling (GMM) provides more insight into this heterogeneity by identifying subgroups of patients with similar response patterns. This study aimed to identify distinct trajectories of disease activity in early RA patients following a T2T strategy, during their first year.
Methods: Data on various clinical and patient-reported measures were collected from the DREAM remission induction cohort. GMM was applied to examine the impact of T2T on subgroups characterized by different types of growth trajectories, as measured with the Disease Activity Score for 28 joints.
Results: Three distinct trajectories of disease activity were found. The normative trajectory contained most patients (82.6%), showing a quickly decreasing disease activity, stabilizing at remission after 9 months. This group performed best on clinical and patient-reported measures over time and were more likely to be men. A smaller group (14.1%) also approached remission, but demonstrated a slower response to treatment. Finally, a minority (3.3%) showed no improvement after 1 year, despite an initial quick decrease in disease activity during the first months of treatment.
Conclusion: Disease activity in early RA patients during the first year of a T2T strategy does not follow a linear pattern, nor is a single developmental trajectory applicable to all patients. Future studies should attempt to identify more specific risk factors for poor outcome to enable early identification of patients in need of alternative therapeutic approaches.

Entities:  

Mesh:

Year:  2014        PMID: 24106173     DOI: 10.1002/acr.22175

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  15 in total

1.  Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy.

Authors:  Peter M Ten Klooster; Martijn A H Oude Voshaar; Walid Fakhouri; Inmaculada de la Torre; Claudia Nicolay; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2019-06-03       Impact factor: 2.980

2.  Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users.

Authors:  Nasir Wabe; Anita Lee; Mihir Wechalekar; Leah McWilliams; Susanna Proudman; Michael Wiese
Journal:  Rheumatol Int       Date:  2017-02-03       Impact factor: 2.631

3.  Further optimization of the reliability of the 28-joint disease activity score in patients with early rheumatoid arthritis.

Authors:  Liseth Siemons; Peter M ten Klooster; Harald E Vonkeman; Mart A F J van de Laar; Cees A W Glas
Journal:  PLoS One       Date:  2014-06-23       Impact factor: 3.240

4.  How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis.

Authors:  Liseth Siemons; Peter M Ten Klooster; Harald E Vonkeman; Piet L C M van Riel; Cees A W Glas; Mart A F J van de Laar
Journal:  BMC Musculoskelet Disord       Date:  2014-11-06       Impact factor: 2.362

5.  Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.

Authors:  Laura M M Steunebrink; Harald E Vonkeman; Peter M ten Klooster; Monique Hoekstra; Piet L C M van Riel; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2016-02-06       Impact factor: 2.980

6.  Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study.

Authors:  D S Courvoisier; D Alpizar-Rodriguez; J E Gottenberg; M V Hernandez; F Iannone; E Lie; M J Santos; K Pavelka; C Turesson; X Mariette; D Choquette; M L Hetland; A Finckh
Journal:  EBioMedicine       Date:  2016-08-18       Impact factor: 8.143

7.  Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH).

Authors:  Cheryl Barnabe; Ye Sun; Gilles Boire; Carol A Hitchon; Boulos Haraoui; J Carter Thorne; Diane Tin; Désirée van der Heijde; Jeffrey R Curtis; Shahin Jamal; Janet E Pope; Edward C Keystone; Susan Bartlett; Vivian P Bykerk
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

8.  Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry.

Authors:  L M M Steunebrink; G A Versteeg; H E Vonkeman; P M Ten Klooster; H H Kuper; T R Zijlstra; P L C M van Riel; M A F J van de Laar
Journal:  Arthritis Res Ther       Date:  2016-03-08       Impact factor: 5.156

9.  Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA.

Authors:  Philip D H Hamann; John D Pauling; Neil McHugh; Kimme Hyrich; Gavin Shaddick
Journal:  Rheumatology (Oxford)       Date:  2020-07-01       Impact factor: 7.580

10.  Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data.

Authors: 
Journal:  RMD Open       Date:  2018-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.